Savara Inc. 8-K Filing Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Savara Inc. on December 7, 2018, reporting events occurring on December 4, 2018. The filing details the entry into a material definitive agreement regarding the company's debt financing structure.
Key Financial Metrics and Debt Structure
The filing outlines a new $45.0 million term loan facility with Silicon Valley Bank (SVB) and its affiliate Life Science Loans II, LLC. Key terms include:
- Total Facility: $45.0 million.
- Tranche A: $25.0 million available immediately; $15.0 million used to refinance existing debt.
- Tranche B: $20.0 million available upon request prior to September 30, 2019, subject to conditions.
- Interest Rate: Prime rate plus 3.00%.
- Repayment Terms: Interest-only through October 31, 2020, followed by equal monthly principal and interest installments over 24 months.
- Maturity Date: November 1, 2022.
- Fees: $0.6 million refinancing fee paid upon entry; 6.0% final payment on aggregate principal advanced.
The filing text does not provide specific values for revenue, profit, cash flow, or operating margins as this is a transactional report rather than a periodic financial statement.
Material Changes and Covenants
The primary material change is the amendment of the Loan and Security Agreement dated April 28, 2017. Significant covenants and conditions include:
- Market Capitalization Collateral Requirement: If Savara's market capitalization falls below $200.0 million for five consecutive trading days following a Tranche B drawdown, the company must provide cash collateral equal to the lesser of the outstanding balance or $20.0 million.
- Collateral Release: Collateral is released if market capitalization exceeds $300.0 million for five consecutive trading days.
- Warrant Issuance:
- Tranche A: Warrants issued to SVB and Life Science to purchase up to 5,666 shares each at an exercise price of $8.824.
- Tranche B: Warrants to purchase shares equal to 1.0% of the funded amount, with an exercise price based on the lesser of the 10-day average or the prior day's closing price.
Outlook, Risks, and Contingencies
Management commentary is limited to the terms of the agreement. The primary risk identified is the liquidity constraint triggered by a decline in market capitalization, which could require the posting of significant cash collateral. The filing notes that the full text of the amendment and warrants will be filed in the Form 10-K for the period ended December 31, 2018.
Investor Verification Checklist
- Verify the exact amount of debt refinanced under Tranche A versus the new capital raised.
- Monitor Savara's market capitalization relative to the $200.0 million and $300.0 million thresholds to assess potential collateral requirements.
- Review the upcoming Form 10-K for the full text of the SVB Warrants and the Second Amendment.
- Confirm the impact of the 6.0% final payment and $0.6 million fee on the company's cash position.
- Assess the dilution impact of the warrants issued to SVB and Life Science.